InsidersTradesSigma
Total declarations
Companies
▲ Purchases (11 ops.)
▼ Sales (9 ops.)
Insider track record
CEODisclosed buys
11
Disclosed sells
9
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the full record of transactions filed by TANG KEVIN C, Director. Insider active across 6 companies, notably La Jolla Pharmaceutical Co. In total, 25 reports have been published. Breakdown: 11 buys · 9 sells. Total volume traded: €9.6m. Activity tracked since 24 May 2021. The latest transaction was disclosed on 14 December 2023 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations25 total
4,394,800 sharesCommon StockSEC:0001415889-24-003784:0
3,850,513 sharesCommon StockSEC:0001415889-24-002278:0
24,406 shares@ US$1.216.2% of flowCommon StockSEC:0001415889-23-016655:0
74,812 shares@ US$0.9715.7% of flowCommon StockSEC:0001209191-23-052788:0
Ideal exit: 7 Jul 2024 (T+270)
347,932 shares@ US$1.0578.1% of flowCommon StockSEC:0001209191-23-033446:0
Ideal exit: 24 Feb 2024 (T+270)
50,000 shares@ US$1.7228.5% of flowCommon StockSEC:0001209191-23-033041:0
Ideal exit: 19 Feb 2024 (T+270)
38,765 shares@ US$1.9524.6% of flowCommon StockSEC:0001209191-23-029527:0
Ideal exit: 5 Feb 2024 (T+270)
57,073 shares@ US$1.9535.9% of flowCommon StockSEC:0001209191-23-028565:0
Ideal exit: 2 Feb 2024 (T+270)
5,300,087 shares@ US$1.8599.3% of flowCommon StockSEC:0001209191-23-027688:0
18,513 shares@ US$1.8511.0% of flowCommon StockSEC:0001209191-23-027833:0
Ideal exit: 28 Jan 2024 (T+270)
65,701 shares@ US$0.9940.7% of flowCommon StockSEC:0001209191-23-018721:0
Ideal exit: 8 Dec 2023 (T+270)
9,607,934 shares@ US$6.2349.2% of flowCommon StockSEC:0001209191-22-047314:0
9,607,934 shares@ US$6.2349.2% of flowCommon StockSEC:0000899243-22-029660:0
193,403 shares@ US$4.100834.4% of flowCommon StockSEC:0001209191-21-067347:0
193,403 shares@ US$4.10080.6% of flowCommon StockSEC:0001209191-21-067347
161,336 shares@ US$13.521642.2% of flowCommon StockSEC:0001209191-21-066910
161,336 shares@ US$13.521634.43% mcap42.2% of flowCommon StockSEC:0001209191-21-066910:0
43,213 shares@ US$9.38457.8% of flowCommon StockSEC:0001209191-21-066146
43,213 shares@ US$9.38456.35% mcap7.8% of flowCommon StockSEC:0001209191-21-066146:0
468,849 shares@ US$2.658350.0% of flowCommon StockSEC:0001209191-21-065826
468,849 shares@ US$2.658350.0% of flowCommon StockSEC:0001209191-21-065826:0
1,286 shares@ US$4.49840.2% of flowCommon StockSEC:0001209191-21-036939
Ideal exit: 21 Feb 2022 (T+270)
1,286 shares@ US$4.49840.2% of flowCommon StockSEC:0001209191-21-036939:0
Ideal exit: 21 Feb 2022 (T+270)
104,403 shares@ US$3.680315.4% of flowCommon StockSEC:0001209191-21-035962
Ideal exit: 18 Feb 2022 (T+270)
104,403 shares@ US$3.680315.4% of flowCommon StockSEC:0001209191-21-035962:0
Ideal exit: 18 Feb 2022 (T+270)
25 of 25 declarations
About TANG KEVIN C
Kevin C. Tang is a Board Member and Chief Executive Officer of La Jolla Pharmaceutical Co., Odonate Therapeutics, Inc., and Aptevo Therapeutics Inc. In his roles, he oversees the strategic and operational leadership of the three companies. Kevin Tang plays a key role in developing new therapeutic solutions and optimizing the performance of the companies. His expertise in biopharmacy and management is essential for the success of these companies.
